Edition:
United Kingdom

China Cord Blood Corp (CO.N)

CO.N on New York Stock Exchange

8.86USD
23 Jan 2018
Change (% chg)

$-0.08 (-0.89%)
Prev Close
$8.94
Open
$8.94
Day's High
$9.00
Day's Low
$8.84
Volume
21,261
Avg. Vol
60,318
52-wk High
$14.95
52-wk Low
$5.07

Summary

Name Age Since Current Position

Yuen Kam

53 2012 Chairman of the Board

Ting Zheng

43 2017 Chief Executive Officer, Director, Chief Executive Officer - Beijing

Albert Chen

39 Chief Financial Officer, Director

Rui Arashiyama

56 Chief Executive Officer - Guangdong and Zhejiang Divisions

Xin Xu

61 Chief Technology Officer

Mark Chen

47 Independent Non-Executive Director

Ken Lu

51 2009 Independent Non-Executive Director

Jennifer Weng

47 Independent Non-Executive Director

Biographies

Name Description

Yuen Kam

Mr. Yuen Kam is Chairman of the Board of the Company. He is responsible for the strategic direction of CCBC. He is also the founder, chairman and chief executive officer of Golden Meditech with over 20 years of experiences in the healthcare industry. Mr. Kam also serves as a non-executive director of CBB. He received his Bachelor of Arts degree in Japanese from the Beijing Second Foreign Languages Institute, the PRC.

Ting Zheng

Ms. Ting Zheng serves as Chief Executive Officer, Director, Chief Executive Officer - Beijing of the Company. She has been in charge of our cord blood bank operations since 2003 and is responsible for the strategic direction, development and overall management of CCBC. Aside from overseeing the overall operation of CCBC, she is also responsible for strategic developments, acquisition planning and negotiations, and formulating overall business strategy and various business initiatives of CCBC. She has more than ten years of experience in the fields of accounting, internal control, and corporate strategies and development in China’s healthcare industry. Ms. Zheng had served as an executive director of Golden Meditech and had been in charge of its and its subsidiaries’ financial and internal control systems since September 2001. She assumed a critical role in the initial public offering by Golden Meditech on the Growth Enterprise Market of the Hong Kong Stock Exchange in December 2001. Ms. Zheng became a non-executive director of Golden Meditech starting from August 2012. She played an important role in our acquisition of Nuoya and investments in Cordlife. Prior to joining us, Ms. Zheng worked for Sino-reality Certified Public Accountants, an accounting firm in China, from 1997 to 2001. She received an Executive MBA degree from Renmin University of China.

Albert Chen

Mr. Albert Chen is Chief Financial Officer, Director of the Company. He is in charge of CCBC’s finance-related matters, including accounting and budget planning. He is also involved in CCBC’s corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies. For example, he played an important role in our acquisition of Nuoya and investments in Cordlife. He had served as the corporate finance vice president of Golden Meditech since March 2005. Prior to joining Golden Meditech, Mr. Chen worked in a number of financial institutions, including SalomonSmithBarney, DBS Vickers Securities and UOB Kay Hian in Hong Kong. During his employment as an analyst in UOB Kay Hian from 2003 to March 2005, he was a senior analyst specializing in the pharmaceutical and healthcare industries and was ranked as one of the best analysts for small cap companies in the region in a poll conducted by Asia Money among brokers in 2003. Mr. Chen is a CFA charterholder. He received his bachelor’s degree in commerce from Queen’s University, Canada, School of Business in 1999 with a major in finance and accounting.

Rui Arashiyama

Ms. Rui Arashiyama is Chief Executive Officer - Guangdong and Zhejiang Divisions of the Company. She oversees the daily operations and management of Nuoya and Lukou and is responsible for the formulation and implementation of marketing strategy for the two markets. She joined Nuoya in March 2009 and has over 10 years of sales and marketing experiences in China and in-depth knowledge about China’s consumer market and regulatory environment. From 1999 to 2009, she worked for Jatco Company Limited and was responsible for new business and new market development, execution and cost management. Between 1989 and 1999, she was with Nissan Motor Company Limited with main responsibilities of overseas market development including China, Hong Kong and Singapore. She graduated from Beijing International Studies University (Beijing Second Foreign Languages Institute, the PRC) in 1981 with a bachelor’s degree of Japanese culture. In 1988, she completed a postgraduate mass media program in Japan Sophia University.

Xin Xu

Ms. Xin Xu is Chief Technology Officer of the Company. She is in charge of the daily operations and logistic control of the cord blood bank laboratories, and oversees the laboratories procedures in relation to the processing, separation and preservation of cord blood stem cells to ensure the laboratories environment strictly comply with national standards. Prior to joining us in November 2004, Ms. Xu has over 20 years of solid experience in Cryobiology research and had lectured in Cryobiology at Beijing Medical University.

Mark Chen

Mr. Mark D. Chen is Independent Non-Executive Director of the Company. Prior to the Business Combination on June 30, 2009, Mr. Chen was Pantheon’s chairman of the board, chief executive officer and president since its inception. He is currently Managing Partner of Pantheon Pacific Capital Management Ltd., a global investment management and advisory company. Since 1998, Mr. Chen has been a founding general partner of Easton Capital Investment Group and its various affiliated funds, a New York based private equity investment firm, and has served in various positions, including managing director and currently a venture partner, a position he has held since 2005. He is currently a director and chairman of the Audit Committee of Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI). Mr. Chen received a B.S. from the Shanghai Jiao Tong University in Shanghai, China, an M.S. from Pennsylvania State University and an M.B.A. from the Columbia Business School at Columbia University.

Ken Lu

Dr. Ken Lu is Independent Non-Executive Director of the Company. Dr. Ken Lu is the chief executive officer of Seres Asset Management Limited (“Seres”), an investment management company focusing on the Asian equity markets. Prior to Seres, Dr. Lu founded and managed APAC Capital Advisors Limited, a Greater China investment specialist, from 2004 to early 2010. Dr. Lu’s extensive capital market experience also includes research analyst roles at a number of leading investment banks, including JP Morgan and Credit Suisse (formerly Credit Suisse First Boston, or “CSFB”). He served as the Head of China Research at CSFB from October 2001 to May 2004. Dr. Lu also serves on the boards and Audit Committee of China Techfaith Wireless Communication Technology Limited and China Biologic Products Inc., both listed on the NASDAQ. Dr. Lu holds a Bachelor of Science degree from the Beijing University, a Master of Science from the Brigham Young University, and a Ph. D. degree in finance from the University of California, Los Angeles.

Jennifer Weng

Ms. Jennifer J. Weng is Independent Non-Executive Director of the Company. Prior to the Business Combination on June 30, 2009, Ms. Weng was Pantheon’s chief financial officer and secretary since its inception. She is currently a Managing Director of Pantheon Pacific Capital Management Ltd., a global investment management and advisory company. Previously, she had held a variety of research and financial management positions with companies including Mizuho and Morgan Stanley in New York. Ms. Weng received a B.A. from Tongji University, China and an M.B.A. from Indiana University of Pennsylvania.

Basic Compensation

Name Fiscal Year Total

Yuen Kam

--

Ting Zheng

345,789

Albert Chen

345,789

Rui Arashiyama

259,602

Xin Xu

135,811

Mark Chen

--

Ken Lu

--

Jennifer Weng

--
As Of  31 Mar 2015

Options Compensation